Podcast Episodes
Back to Search
Ep. 296 - Trends in Obesity, Vinay Prasad at FDA, Ovarian Cancer Insights
Season 6 Episode 296
Biopharmas developing therapies for obesity are looking to a future where the quality of weight loss matters as much as the quantity — what targets a…
1 year, 3 months ago
Ep. 295 - Bio€quity Europe 2025 Preview
Season 6 Episode 295
This year’s Bio€quity Europe conference — the 25th edition of the event — will focus on what’s next for Europe amid biotech’s current complex moment,…
1 year, 4 months ago
Ep. 294 - AACR Spotlight on SMARCA2 degraders. Plus: David Baker, Drug Pricing
Season 6 Episode 294
Among the formerly undruggable targets gaining translational momentum, SMARCA2 has intrigued researchers for its potential to treat challenging solid…
1 year, 4 months ago
Ep. 293 - Tau Time for Alzheimer's. Plus: FDA Delays, Merck's $4B Deal, HK IPOs
Season 6 Episode 293
Belief in tau — both as a target and surrogate endpoint — for Alzheimer’s is building among leaders in the field. On the latest BioCentury This Week …
1 year, 4 months ago
Ep. 292 - Myasthenia Gravis Spotlight & AACR Preview
Season 6 Episode 292
Biopharma companies are vying to dethrone Vyvgart as a leading therapy for myasthenia gravis, with the latest data for therapies treating the rare au…
1 year, 4 months ago
Ep. 291 - Grand Rounds - U.S. Preview
Season 6 Episode 291
The academia-industry interface is more important than ever for sustaining biomedical innovation’s forward momentum, even as the Trump administration…
1 year, 4 months ago
Ep. 290 - Biotech Survey Sees Tough Days Ahead. Plus: FDA, China Speed
Season 6 Episode 290
The biotech community is reeling, fearful and furious about the fallout of tariff, FDA and NIH policies, according to BioCentury’s newly released Ris…
1 year, 4 months ago
Ep. 289 - Replacing Animal Models. Plus: RFK Jr. & FDA
Season 6 Episode 289
FDA’s plan to move away from animal toxicity testing could expedite INDs and cut costs for biopharma companies, while helping the U.S. maintain its p…
1 year, 4 months ago
Ep. 288 - FDA and Tariffs Turmoil, and AACR Preview
Season 6 Episode 288
Loss of leadership, cuts to staffing and a proposed reorganization at FDA have heightened biotech risk amid an already turbulent macroeconomic climat…
1 year, 5 months ago
Ep. 287 - The Bear is Back: Marks’ Ouster, Tariffs and a Tumbling XBI
Season 6 Episode 287
Biotech indexes are tumbling after one of FDA’s last veteran leaders was pushed out by HHS Secretary RFK Jr. and the threat of tariffs weigh on a key…
1 year, 5 months ago